Autologous engineered T-cell therapy with a logic-gate circuit to recognize PSMA and CA9; CAR-like activation enabling targeted cytotoxicity against clear-cell renal cell carcinoma. Administered as a single IV infusion; designed to enhance tumor specificity and reduce off-tumor toxicity.
Autologous T cells engineered with a PSMA-inducible anti-CA9 CAR (logic-gate circuit). Engagement of PSMA triggers expression of an anti-CA9 CAR, enabling CAR-like activation and cytotoxic killing of PSMA/CA9-expressing tumor cells. Embedded shRNA-miR modules downregulate Fas and TGFβRII to resist apoptosis and TGF-β–mediated immunosuppression, and a constitutive activator enhances STAT3 signaling to promote T-cell expansion and function, improving specificity and reducing off-tumor toxicity.
NO
INDIRECT
Fas (CD95) is not a killing target; it is downregulated within the engineered T cells to prevent their apoptosis. The drug’s cytotoxicity is directed against PSMA/CA9-positive tumor cells via CAR-mediated T-cell killing, not against Fas-expressing cells.
Autologous engineered T-cell therapy with a logic-gate circuit to recognize PSMA and CA9; CAR-like activation enabling targeted cytotoxicity against clear-cell renal cell carcinoma. Administered as a single IV infusion; designed to enhance tumor specificity and reduce off-tumor toxicity.
Autologous T cells engineered with a PSMA-inducible anti-CA9 CAR (logic-gate circuit). Engagement of PSMA triggers expression of an anti-CA9 CAR, enabling CAR-like activation and cytotoxic killing of PSMA/CA9-expressing tumor cells. Embedded shRNA-miR modules downregulate Fas and TGFβRII to resist apoptosis and TGF-β–mediated immunosuppression, and a constitutive activator enhances STAT3 signaling to promote T-cell expansion and function, improving specificity and reducing off-tumor toxicity.
NO
INDIRECT
TGF-βRII is not a kill target; it is knocked down within the engineered T cells to block TGF-β signaling. Killing is via induced anti-CA9 CAR activity against PSMA/CA9-positive tumor cells, not TGF-βRII–expressing cells.
Anti-CD20 monoclonal antibody that depletes malignant B cells via complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and induces cell death via complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis, leading to depletion of CD20+ malignant B cells.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers complement-dependent cytotoxicity, Fc-mediated ADCC by effector cells (e.g., NK cells), and can induce apoptosis, leading to direct killing of CD20+ cells.
Anti-CD19 antibody–drug conjugate that delivers the PBD dimer tesirine to CD19+ B cells, causing DNA cross-links and cytotoxicity after internalization.
Humanized anti‑CD19 monoclonal antibody linked via a cleavable linker to the pyrrolobenzodiazepine (PBD) dimer tesirine. After binding CD19 on B cells and internalization, the linker is cleaved to release the PBD payload, which binds the DNA minor groove and forms interstrand crosslinks at N2‑guanine, inhibiting DNA replication and inducing cytotoxicity in CD19+ tumor cells.
YES
DIRECT
The anti-CD19 ADC binds CD19, is internalized, and releases the PBD dimer tesirine via a cleavable linker; the payload forms DNA interstrand crosslinks (N2-guanine), inhibiting replication and killing CD19+ cells.
Anti-CD19 antibody–drug conjugate that delivers the PBD dimer tesirine to CD19+ B cells, causing DNA cross-links and cytotoxicity after internalization.
Humanized anti‑CD19 monoclonal antibody linked via a cleavable linker to the pyrrolobenzodiazepine (PBD) dimer tesirine. After binding CD19 on B cells and internalization, the linker is cleaved to release the PBD payload, which binds the DNA minor groove and forms interstrand crosslinks at N2‑guanine, inhibiting DNA replication and inducing cytotoxicity in CD19+ tumor cells.
NO
INDIRECT
The ADC binds CD19 on B cells, is internalized, and releases a PBD payload that crosslinks DNA at N2‑guanine in the minor groove, blocking replication and killing CD19+ cells; the DNA minor groove is not the antigen targeted by the drug.